Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
June 6th 2023At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
2 Clarke Drive
Cranbury, NJ 08512